Perspectives on Indirect Comparisons of BTK Inhibitors for R/R CLL/SLL

Opinion
Video

Mazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.

Video content above is prompted by the following question:

  • How do the latest analyses of zanubrutinib compare with other BTK inhibitors in relapsed/refractory CLL/SLL?

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
Related Content
Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL

Pirtobrutinib Outperforms Standard Options in Relapsed/Refractory CLL/SLL

Sabrina Serani
June 23rd 2025
Article

Pirtobrutinib shows significant benefits in progression-free survival and tolerability for relapsed CLL patients compared to standard treatments.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

BGB-16673 Shows Promise in Relapsed/Refractory CLL/SLL

BGB-16673 Shows Promise in Relapsed/Refractory CLL/SLL

Gina Mauro
June 19th 2025
Article

New trial results reveal BGB-16673's promising safety and efficacy in treating relapsed CLL/SLL, showing significant antitumor activity across diverse patient profiles.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

Jax DiEugenio
June 17th 2025
Article

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.

Read More

Novel Agent DZD8586 Shows Promise in Heavily Pretreated CLL

Novel Agent DZD8586 Shows Promise in Heavily Pretreated CLL

Jason M. Broderick
June 16th 2025
Article

DZD8586 achieved a high response rate in patients with relapsed/refractory CLL/SLL.

Read More